image alt text

Principal Investigator

Avatar

Kyle A. Cottrell

Purdue University

Assistant Professor of Biochemistry

RNA editing, post-transcriptional regulation, cancer

Lab Manager

Avatar

Holly Bohlin

Purdue University

Lab Manager and Research Technician

cancer, bioinformatics, RNA therapeutics

Graduate Students

Avatar

Addison Young

Purdue University

Graduate Student

Protein Structure-Function Relationships, Cancer Development

Researchers

Avatar

Jackson Pierce

Purdue University

Research Technician

ALS-related proteinopathy, cancer, genetics

Undergraduate Researchers

Avatar

David Onishile

Purdue University

Undergraduate Researcher

Cancer cell culture, immunology, gene editing

Avatar

Estelle Gardner

Purdue University

Undergraduate Researcher

Human disease and therapeutics

Avatar

Madison Liu

Purdue University

Undergraduate Researcher

cancer, therapeutics, protein engineering

Avatar

Renee Chua

Purdue University

Undergraduate Researcher

Cancer, immunotherapy, drug discovery

Philosophy

We recognize that the pursuit of scientific knowledge is not an equitable endeavor. Systematic biases often influence who can pursue academic research. To that end, it is the goal of this laboratory to do our part to make that pursuit equitable. We will do so by making the laboratory an inclusive and diverse workplace by following the below tenets:

  1. Sexism, racism, classism, or other forms of discrimination have no place in the laboratory.

  2. Every member of the lab has a voice, and their voice should be heard.

  3. Inclusivity and diversity will make our team stronger.

  4. Everyone in the laboratory is entitled to appropriate training, resources, and mentorship.

We will make every effort to ensure that our work is robust, reproducible, and accessible.

Publications

(2024). The competitive landscape of the dsRNA world. Molecular Cell.

PDF DOI

(2023). Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells. bioRxiv.

PDF DOI

(2021). 8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR. Cancer Research Communications.

PDF DOI

(2021). Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene.

PDF DOI

(2020). Upregulation of 5′-terminal oligopyrimidine mRNA translation upon loss of the ARF tumor suppressor. Scientific Reports.

PDF DOI

(2019). A short translational ramp determines the efficiency of protein synthesis. Nature Communications.

PDF DOI

(2018). PTRE-seq reveals mechanism and interactions of RNA binding proteins and miRNAs. Nature Communications.

PDF DOI

(2017). Translation efficiency is a determinant of the magnitude of miRNA-mediated repression. Scientific Reports.

PDF DOI

(2011). Sirtuin-mediated nuclear differentiation and programmed degradation in Tetrahymena. BMC Cell Biology.

PDF DOI

Contact